Peptide Sciences Tirzepatide vs Semaglutide vs Retatrutide – A Research Comparison
The incretin peptide science tirzepatide family has expanded dramatically over the past decade. Researchers now have access to multiple receptor-targeting strategies, from selective GLP-1 agonism to dual and triple receptor activation. This evolution mirrors the broader trend in precision medicine, where multi-targeted approaches are increasingly investigated for complex metabolic conditions.
Semaglutide, tirzepatide, and retatrutide represent three distinct generations of research peptides targeting metabolic pathways. Understanding their differences – receptor profiles, half-lives, signaling biases, and research applications – is essential for designing rigorous preclinical studies.
This comprehensive comparison guide examines all three peptides available from Peptide Sciences™ , helping researchers select the right tool for their specific experimental questions.
For additional context, commercial information on GLP-1-based therapies can be found at NovoWegovy , and other research suppliers like Paramount Peptides also offer similar compounds. However, as emphasized in our guide on where to buy research peptides , always verify quality standards regardless of supplier.
Three Peptides, Three Mechanisms
At a Glance Comparison Table
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Number of agonists | Single | Dual (two) | Triple (three) |
| Half-life (animal models) | ~7 days | ~5 days | ~6 days |
| Molecular weight (Da) | 4,113.6 | 4,813.4 | ~4,900 |
| Amino acid length | 31 | 39 | ~40 |
| Peptide Sciences™ purity | ≥99% | ≥98.5% | ≥98% |
| Primary research use | Selective GLP-1 studies | Dual pathway mapping | Triple-receptor signaling |
| Fatty acid modification | C18 at Lys26 | C20 at Lys20 | C18/C20 hybrid |
| DPP-4 resistance | Yes (Aib substitutions) | Yes (Aib substitutions) | Yes (Aib substitutions) |
| SKU | PS-SEMA-5mg | PS-TIRZ-10mg | PS-RETA-10mg |
The Incretin System: Background for Researchers
Before diving into each peptide, a brief overview of the incretin system is helpful.
Incretins are gut-derived hormones that potentiate insulin secretion in response to meals. The two primary incretins are:
| Hormone | Receptor | Primary Effects | Secreted By |
|---|---|---|---|
| GLP-1 (Glucagon-Like Peptide-1) | GLP-1R | Insulin secretion, satiety, gastric emptying | L-cells (ileum, colon) |
| GIP (Glucose-dependent Insulinotropic Polypeptide) | GIP-R | Insulin secretion, fat metabolism, bone turnover | K-cells (duodenum) |
| Glucagon | Glucagon-R | Glucose production, energy expenditure, thermogenesis | Alpha-cells (pancreas) |
Native GLP-1 and GIP are rapidly degraded by the enzyme DPP-4 (dipeptidyl peptidase-4), with half-lives of only 1–2 minutes. All three peptides discussed here have been structurally modified to resist DPP-4 degradation, extending their half-lives to days rather than minutes.
Semaglutide: The Selective GLP-1 Agonist
Molecular Structure and Properties
Peptide sciences semaglutide is a modified GLP-1 analog with key structural modifications that distinguish it from native GLP-1 and earlier analogs like liraglutide:
| Modification | Position | Purpose | Effect |
|---|---|---|---|
| Substitution of Ala8 with Aib | Position 8 | Prevents DPP-4 degradation | Extends half-life from 2 min to ~7 days |
| Lys26 fatty acid acylation | Position 26 | Enables albumin binding | Slows renal clearance |
| C18 fatty diacid (octadecanedioic acid) | Attached via spacer | Enhances receptor affinity and duration | Balanced potency and half-life |
| Spacer (Glu-2xOEG) | Between Lys26 and C18 | Optimizes albumin binding | Prevents aggregation |
These modifications represent decades of peptide engineering. The result is a molecule that retains high GLP-1 receptor potency while achieving a half-life suitable for once-weekly dosing in animal models.
Structural Comparison to Native GLP-1
| Feature | Native GLP-1 (7-37) | Semaglutide |
|---|---|---|
| Sequence length | 31 amino acids | 31 amino acids (modified) |
| DPP-4 half-life | <2 minutes | >48 hours |
| Albumin binding | None | High (via C18 fatty acid) |
| Receptor potency (cAMP) | EC50 ~0.05 nM | EC50 ~0.1 nM |
| Selectivity | GLP-1R only | GLP-1R only (>10,000x over GIP-R, glucagon-R) |
Receptor Pharmacology
Semaglutide is highly selective for the GLP-1 receptor (GLP-1R) with no significant cross-reactivity at relevant concentrations:
| Receptor | Binding Affinity (IC50) | Relative to GLP-1R |
|---|---|---|
| GLP-1R (human) | ~1 nM | 1x |
| GIP-R (human) | >10,000 nM | >10,000x lower |
| Glucagon-R (human) | >10,000 nM | >10,000x lower |
| GCGR-related receptors | No binding | N/A |
Signaling bias: Semaglutide exhibits balanced signaling between cAMP (G-protein-dependent) and β-arrestin recruitment pathways. This contrasts with some biased agonists that preferentially activate one pathway over the other.
| Signaling Pathway | Potency (EC50) | Efficacy (% max) |
|---|---|---|
| cAMP accumulation | ~0.1 nM | 100% |
| β-arrestin recruitment | ~10 nM | 80% |
| ERK phosphorylation | ~1 nM | 90% |
Research Applications
Semaglutide is best suited for:
1. Isolated GLP-1 pathway studies – No confounding GIP or glucagon activity. This is the cleanest system for studying GLP-1-specific effects.
2. Appetite regulation research – Hypothalamic feeding circuits express high levels of GLP-1R. Semaglutide activates these receptors without off-target effects.
3. Gastric emptying assays – Measures GLP-1-specific effects on motility using phenol red or acetaminophen absorption methods.
4. Pancreatic beta-cell function – GLP-1’s role in glucose-stimulated insulin secretion (GSIS) can be studied in isolation.
5. Pharmacokinetic studies – Extended half-life peptide analogs can be characterized using semaglutide as a benchmark.
6. Cardiovascular research – GLP-1R is expressed in cardiac tissue and vascular endothelium. Semaglutide allows study of GLP-1-specific cardioprotective effects.
Advantages for Research
| Advantage | Why It Matters |
|---|---|
| Single receptor target | Cleaner mechanistic interpretation – no pathway cross-talk |
| Long half-life (~7 days) | Once-daily or once-weekly dosing reduces handling stress in vivo |
| Well-characterized | Extensive literature (500+ publications) for comparison across studies |
| High selectivity (>10,000x) | No off-target receptor activation at physiological doses |
| Commercial relevance | Semaglutide is the benchmark against which newer peptides are compared |
Limitations
| Limitation | Consideration |
|---|---|
| No GIP activity | Cannot study dual agonism or GIP-specific effects |
| No glucagon activity | Cannot study energy expenditure via glucagon pathways |
| Higher molecular weight (vs native) | May affect tissue distribution compared to smaller peptides |
| Albumin binding | May reduce free fraction in protein-rich assay buffers |
Sample Semaglutide Research Protocol (In Vivo)
| Parameter | Recommendation |
|---|---|
| Typical dose (mouse) | 10–30 nmol/kg (40–120 μg/kg) |
| Frequency | Once every 3 days or once weekly |
| Route | Subcutaneous |
| Reconstitution | Sterile saline or PBS |
| Vehicle | 0.1% BSA in saline (prevents adsorption) |
| Positive control | Exendin-4 (short-acting GLP-1 agonist) |
| Negative control | Saline or scrambled peptide |
Tirzepatide: The Dual GLP-1/GIP Agonist
Molecular Structure and Properties
Peptide sciences tirzepatide is a synthetic 39-amino acid peptide engineered to activate both GLP-1 and GIP receptors with balanced potency. It represents a significant structural departure from semaglutide.
| Structural Feature | Description | Purpose |
|---|---|---|
| GIP sequence backbone | Based on native GIP (1-42) | Provides GIP receptor activity |
| Modified at positions 2, 13, 14 | Aib substitutions and other modifications | Enhances GLP-1 activity and DPP-4 resistance |
| C20 fatty diacid (eicosanedioic acid) at Lys20 | Longer chain than semaglutide | Albumin binding, extended half-life |
| Spacer (Glu-2xOEG) | Between Lys20 and C20 | Optimizes albumin binding and solubility |
| Truncated C-terminus | Removes native GIP C-terminal tail | Improves receptor selectivity profile |
Receptor Pharmacology
Tirzepatide is a balanced dual agonist with nearly equipotent activity at both GLP-1R and GIP-R:
| Receptor | Binding Affinity (IC50) | cAMP Potency (EC50) | Relative Potency |
|---|---|---|---|
| GLP-1R (human) | ~1 nM | ~0.5 nM | 1x |
| GIP-R (human) | ~0.5 nM | ~0.3 nM | ~1.5x more potent at GIP-R |
| Glucagon-R | >10,000 nM | Not active | >10,000x selective |
Key distinction from semaglutide: Tirzepatide activates GIP-R with slightly higher potency than GLP-1R. This contrasts with earlier dual agonists that strongly favored one receptor over the other.
Signaling profile:
| Receptor | cAMP | β-arrestin | ERK |
|---|---|---|---|
| GLP-1R | +++ (EC50 ~0.5 nM) | ++ (EC50 ~5 nM) | ++ |
| GIP-R | +++ (EC50 ~0.3 nM) | + (EC50 ~20 nM) | + |
Unlike single agonists, tirzepatide activates both receptors simultaneously, producing additive or synergistic effects in some research models. The GIP component is particularly interesting because GIP-R is expressed on adipocytes, pancreatic beta cells, and bone.
Research Applications
Tirzepatide is best suited for:
1. Dual pathway mapping – Comparing GLP-1-only vs GLP-1+GIP activation using semaglutide as control.
2. Metabolic syndrome models – Obesity, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
3. Beta-cell preservation studies – Both GLP-1R and GIP-R are expressed on pancreatic beta cells; dual activation may produce distinct effects on beta-cell survival and function.
4. Adipose tissue research – GIP receptors are abundant on adipocytes, where they influence lipid metabolism and fat distribution.
5. Comparative efficacy studies – Single (GLP-1 only) vs dual (GLP-1+GIP) agonism in the same research model.
6. Bone metabolism research – GIP receptors are expressed on osteoblasts and osteoclasts, making tirzepatide a tool for studying the bone-incretin axis.
Advantages for Research
| Advantage | Why It Matters |
|---|---|
| Dual receptor activation | Models next-generation therapeutic strategies beyond single agonists |
| Balanced potency (1:1 ratio) | Neither receptor dominates, allowing study of integrated signaling |
| Extended half-life (~5 days) | Once-weekly dosing practical for chronic studies |
| Distinct from semaglutide | Enables comparative studies (GLP-1 only vs GLP-1+GIP) |
| GIP component understudied | Opportunity to discover novel GIP-mediated effects |
Limitations
| Limitation | Consideration |
|---|---|
| No glucagon activity | Cannot study triple agonism or glucagon-specific pathways |
| More complex interpretation | Two pathways to deconvolute; requires GLP-1-only control (semaglutide) |
| Less literature than semaglutide | Fewer published studies for comparison (though growing rapidly) |
| Higher molecular weight | May affect tissue distribution compared to smaller peptides |
Sample Tirzepatide Research Protocol (In Vivo)
| Parameter | Recommendation |
|---|---|
| Typical dose (mouse) | 10–30 nmol/kg (50–150 μg/kg) |
| Frequency | Once every 3 days or once weekly |
| Route | Subcutaneous |
| Reconstitution | Sterile saline or PBS |
| Control groups needed | Saline (negative), Semaglutide (GLP-1 only control) |
| Endpoint examples | Food intake, body weight, glucose tolerance, insulin levels |
Experimental Design: Tirzepatide vs Semaglutide
To determine whether GIP activation adds value over GLP-1 alone:
| Group | Treatment | Interpretation |
|---|---|---|
| 1 | Vehicle (saline) | Baseline |
| 2 | Semaglutide (GLP-1 only) | GLP-1 effect size |
| 3 | Tirzepatide (GLP-1 + GIP) | Combined effect |
| 4 | GIP-only agonist (if available) | GIP-alone effect |
Statistical comparison: If Group 3 > Group 2, GIP activation contributes additional effects beyond GLP-1 alone.
Retatrutide: The Triple GLP-1/GIP/Glucagon Agonist
Molecular Structure and Properties
Peptide sciences retatrutide (also known as LY3437943) is a next-generation triple agonist representing the most complex incretin-based research peptide commercially available.
| Structural Feature | Description | Purpose |
|---|---|---|
| Engineered backbone | Unnatural amino acid sequence not based on native GLP-1, GIP, or glucagon | Activates all three receptors with balanced design |
| Balanced design | No single receptor dominates the signaling profile | Allows study of integrated triple-receptor effects |
| Fatty acid acylation | C18 or C20 fatty acid (proprietary) | Extended half-life (~6 days) |
| Aib substitutions | Multiple positions | DPP-4 resistance and protease stability |
| Optimized C-terminus | Modified from native sequences | Improves receptor selectivity |
Receptor Pharmacology
Retatrutide activates three distinct receptors with the following profile:
| Receptor | cAMP Potency (EC50) | Relative Activity | Binding Affinity |
|---|---|---|---|
| GLP-1R (human) | ~0.1 nM | +++ (highest) | High (low nM) |
| GIP-R (human) | ~0.1 nM | +++ (highest) | High (low nM) |
| Glucagon-R (human) | ~0.5 nM | ++ (moderate) | Moderate (mid nM) |
Key insight: Retatrutide is GLP-1 and GIP dominant with moderate glucagon activity. This design prioritizes the satiety and insulinotropic effects (GLP-1/GIP) while adding thermogenic and energy expenditure effects (glucagon).
The glucagon receptor component is particularly interesting for research on:
-
Energy expenditure – Glucagon increases thermogenesis in brown adipose tissue
-
Fatty acid oxidation – Glucagon promotes lipid utilization over glucose
-
Hepatic glucose production – Glucagon stimulates gluconeogenesis and glycogenolysis
-
Amino acid metabolism – Glucagon increases ureagenesis
Why Glucagon Matters in Research
Glucagon has historically been viewed as the counter-regulatory hormone to insulin. However, emerging research suggests glucagon has additional effects relevant to metabolic studies:
| Effect | Mechanism | Research Relevance |
|---|---|---|
| Thermogenesis | Activation of brown adipose tissue via sympathetic nervous system | Energy expenditure studies |
| Lipid oxidation | Increased fatty acid utilization in liver and muscle | Metabolic flexibility assays |
| Satiety | Central effects via hepatic vagal afferents | Appetite regulation (alongside GLP-1) |
| Hepatic glucose output | Glycogenolysis and gluconeogenesis | Glucose homeostasis models |
The triple agonist approach allows researchers to study these glucagon-mediated effects alongside GLP-1 and GIP signaling in a single molecule.
Research Applications
Retatrutide is best suited for:
1. Triple-receptor signaling mapping – All three pathways simultaneously. This is the first commercially available tool for such studies.
2. Energy homeostasis research – Glucagon’s thermogenic effects on brown adipose tissue and energy expenditure.
3. Comparative metabolic studies – Single (semaglutide) vs dual (tirzepatide) vs triple (retatrutide) agonism in the same model.
4. Precision medicine models – Which receptor combination (GLP-1 only, GLP-1+GIP, or triple) produces optimal outcomes in different research contexts?
5. Advanced obesity and metabolic research – Multiple pathways to satiety (GLP-1, GIP, glucagon) and energy expenditure (glucagon).
6. NAFLD/NASH research – Glucagon reduces hepatic steatosis; triple agonism may have distinct effects on liver fat.
Advantages for Research
| Advantage | Why It Matters |
|---|---|
| Triple receptor activation | State-of-the-art research tool – first commercially available triple agonist |
| Glucagon activity unique | Only retatrutide offers glucagon-mediated energy expenditure pathway among these three |
| Novel mechanism (limited literature) | Significant discovery opportunity – many unanswered questions |
| Extended half-life (~6 days) | Practical for chronic in vivo studies |
| All three pathways in one molecule | Reduces variability from co-administration of separate peptides |
Limitations
| Limitation | Consideration |
|---|---|
| Most complex interpretation | Three pathways to deconvolute; requires single and dual agonist controls |
| Newest molecule (2020s) | Less published literature available for comparison (but growing rapidly) |
| Higher molecular weight (~4,900 Da) | May affect tissue distribution vs smaller peptides |
| Glucagon activity moderate | Not full glucagon agonist; effects may differ from pure glucagon |
| Limited commercial analogs | Fewer validated assays and antibodies compared to GLP-1-only tools |
Sample Retatrutide Research Protocol (In Vivo)
| Parameter | Recommendation |
|---|---|
| Typical dose (mouse) | 5–20 nmol/kg (25–100 μg/kg) – lower than single/dual due to potency |
| Frequency | Once every 3 days or once weekly |
| Route | Subcutaneous |
| Reconstitution | Sterile saline or PBS with 0.1% BSA |
| Control groups needed | Saline, Semaglutide (GLP-1 only), Tirzepatide (GLP-1+GIP) |
| Special endpoints (glucagon-specific) | Core body temperature, energy expenditure (indirect calorimetry), hepatic glucose output |
Experimental Design: Comparing All Three Peptides
To determine the contribution of each receptor pathway:
| Group | Treatment | Pathways Activated | Interpretation |
|---|---|---|---|
| 1 | Vehicle (saline) | None | Baseline control |
| 2 | Semaglutide | GLP-1 only | GLP-1 effect size |
| 3 | Tirzepatide | GLP-1 + GIP | Additive GIP effect (Group 3 – Group 2) |
| 4 | Retatrutide | GLP-1 + GIP + glucagon | Additive glucagon effect (Group 4 – Group 3) |
| 5 | GIP-only agonist (if available) | GIP only | Isolated GIP effect |
| 6 | Glucagon-only (native or analog) | Glucagon only | Isolated glucagon effect |
This design allows researchers to parse the contribution of each receptor pathway to the overall phenotype.
Head-to-Head Comparison: Which Peptide for Which Research Question?
I want to study isolated GLP-1 effects without confounding from other pathways
Recommendation: Semaglutide
Reasoning: Semaglutide is highly selective for GLP-1R with no significant GIP or glucagon activity at relevant concentrations. Tirzepatide or retatrutide would introduce confounding pathway activation that complicates interpretation.
ReI want to compare single vs dual agonism (GLP-1 only vs GLP-1+GIP)
Recommendation: Semaglutide + Tirzepatide
Reasoning: Use semaglutide (GLP-1 only) as the control condition. Use tirzepatide (GLP-1+GIP) as the dual agonist test condition. Any difference between groups is attributable to GIP activation. This is a clean experimental design.
I want to study triple receptor activation (GLP-1, GIP, and glucagon simultaneously)
Recommendation: Retatrutide
Reasoning: Only retatrutide engages all three receptors in a single molecule. No other commercial research peptide offers this triple agonist profile.
I want the longest possible half-life for infrequent dosing (to minimize handling stress)
Recommendation: Semaglutide (or Retatrutide)
Reasoning: Semaglutide has the longest published half-life in animal models (~7 days). Retatrutide is similar (~6 days). Tirzepatide is slightly shorter (~5 days). All three support once-weekly dosing.
I want to study energy expenditure and thermogenesis
Recommendation: Retatrutide
Reasoning: Only retatrutide activates glucagon receptors among these three peptides. Glucagon is directly linked to thermogenesis in brown adipose tissue, fatty acid oxidation, and energy expenditure. If you need a pure glucagon control, consider native glucagon or a selective glucagon agonist.
I want the most literature available for comparison with published studies
Recommendation: Semaglutide
Reasoning: Semaglutide has been studied in hundreds of publications across multiple research areas. Tirzepatide has dozens of publications. Retatrutide is newest with the least published data – but this also represents the greatest discovery opportunity.
I want to study beta-cell function and insulin secretion
Recommendation: Tirzepatide (or compare all three)
Reasoning: Both GLP-1R and GIP-R are expressed on pancreatic beta cells. Dual activation (tirzepatide) may produce distinct effects on glucose-stimulated insulin secretion compared to GLP-1 alone (semaglutide). Triple activation (retatrutide) adds glucagon, which may have indirect effects via glucose levels.
I want to study adipose tissue and lipid metabolism
Recommendation: Tirzepatide (or Retatrutide)
Reasoning: GIP receptors are abundant on adipocytes, where they influence lipid storage and mobilization. Tirzepatide’s GIP component makes it valuable for adipose research. Retatrutide adds glucagon’s effects on fatty acid oxidation.
Experimental Design Considerations
Dosing Comparison (In Vivo Rodent Models)
| Peptide | Typical Dose (mouse, SC) | Frequency | Volume | Reconstitution |
|---|---|---|---|---|
| Semaglutide | 10–30 nmol/kg (40–120 μg/kg) | Once every 3-7 days | 50-100 μL | Saline + 0.1% BSA |
| Tirzepatide | 10–30 nmol/kg (50–150 μg/kg) | Once every 3-7 days | 50-100 μL | Saline + 0.1% BSA |
| Retatrutide | 5–20 nmol/kg (25–100 μg/kg) | Once every 3-7 days | 50-100 μL | Saline + 0.1% BSA |
Note: Exact dosing depends on specific research model, strain, and endpoint. Perform pilot dose-response studies to optimize for your system.
Endpoint Selection by Peptide
| Endpoint | Semaglutide | Tirzepatide | Retatrutide | Best For |
|---|---|---|---|---|
| Food intake (acute, 0-24h) | ✓✓✓ (strong) | ✓✓✓ | ✓✓✓ | All three |
| Food intake (chronic, daily) | ✓✓ | ✓✓✓ | ✓✓✓ | Tirzepatide or Retatrutide |
| Body weight change | ✓✓ | ✓✓✓ | ✓✓✓✓ | Retatrutide (adds glucagon) |
| Glucose tolerance (OGTT/IPGTT) | ✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | Tirzepatide or Retatrutide |
| Insulin secretion (GSIS) | ✓✓✓ | ✓✓✓✓ | ✓✓✓ | Tirzepatide (GIP adds effect) |
| Energy expenditure (indirect calorimetry) | ✓ | ✓ | ✓✓✓✓ | Retatrutide (glucagon effect) |
| Core body temperature | – | – | ✓✓✓ | Retatrutide only |
| Hepatic steatosis (NAFLD model) | ✓✓ | ✓✓✓ | ✓✓✓✓ | Retatrutide (glucagon effect) |
| Gastric emptying | ✓✓✓ | ✓✓✓ | ✓✓ | Semaglutide or Tirzepatide |
Key: ✓ = measurable effect; more ✓ = stronger effect.
Choosing Control Groups
| Comparison Question | Control Group Needed |
|---|---|
| “Does my peptide work?” | Vehicle (saline) only |
| “Is the effect GLP-1 mediated?” | GLP-1 antagonist (exendin 9-39) |
| “Is GIP adding anything beyond GLP-1?” | Semaglutide (GLP-1 only) |
| “Is glucagon adding anything beyond GLP-1+GIP?” | Tirzepatide (GLP-1+GIP) |
Quality Standards for GLP-1 Family Research Peptides
All three peptides from Peptide Sciences™ meet rigorous quality standards:
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| HPLC purity | ≥99% | ≥98.5% | ≥98% |
| Net peptide content | ≥85% | ≥85% | ≥85% |
| Endotoxin | <0.5 EU/mg | <0.5 EU/mg | <0.5 EU/mg |
| Mass spec confirmation | ±0.5 Da | ±0.5 Da | ±0.5 Da |
| COA type | Batch-specific | Batch-specific | Batch-specific |
| Stability (lyophilized) | 24 months at -20°C | 24 months at -20°C | 24 months at -20°C |
As discussed in our peptide quality verification guide , always request batch-specific COAs before purchasing from any supplier.
Frequently Asked Questions About GLP-1 Family Research Peptides
Q: Can I use these peptides interchangeably in my research?
A: No. They activate different receptor combinations. Semaglutide is GLP-1 only; tirzepatide adds GIP; retatrutide adds glucagon. Choose based on your research question.
Q: Which one has the longest half-life?
A: Semaglutide (~7 days) > Retatrutide (~6 days) > Tirzepatide (~5 days). All support once-weekly dosing.
Q: Do these peptides cross the blood-brain barrier?
A: Evidence suggests they can access hypothalamic feeding centers via areas where the BBB is permeable (circumventricular organs). The exact mechanisms are still under investigation.
Q: Can I use these peptides in cell culture?
A: Yes, but use endotoxin-tested versions (<1 EU/mg). Concentrations of 1-100 nM are typical. Note that albumin in serum will bind fatty-acid-modified peptides, potentially reducing free fraction.
Q: What’s the best way to reconstitute these peptides?
A: Use sterile saline or PBS with 0.1% bovine serum albumin (BSA) to prevent adsorption to plastic surfaces. Avoid vortexing; gently swirl instead.
Q: How do I store reconstituted solutions?
A: At 4°C for up to 7 days. For longer storage, aliquot and freeze at -20°C or -80°C. Avoid repeated freeze-thaw cycles.
Q: Can I combine these peptides with BPC-157 in the same study?
A: Possibly, depending on your research question. Some researchers study GLP-1 agonists alongside tissue-repair peptides like BPC-157 (see our BPC-157 research guide ). Always test combinations in pilot studies.
Q: Are these peptides approved for human use?
A: No. All Peptide Sciences™ products are for laboratory research use only. Semaglutide and tirzepatide have commercial names for clinical use, but our products are research-grade only.
